Publications scientifiques HUDERF

Faire progresser la recherche pédiatrique : accueillir l'innovation et soutenir l'excellence

Publications scientifiques HUDERF

  • Long-term MAPK inhibition of childhood refractory-Langerhans cell histiocytosis: an observational study on 288 patients.

  • Auteurs Donadieu J, Evseev D, Pegoraro F, Sieni E, Slater O, Hutter C, Astigarraga I, Lehrnbecher T, van den Bos C, Simonin M, Ahlmann M, Barkaoui M, Le Louet S, Chevallier A, Chalard F, Nguyen T, Holzhauer S, Beutel K, Haenicke H, Escherich G, Garcia-Obregon S, Valero-Arrese L, Ruano D, Andres M, Habes D, Lacaille F, McLin V, Bomken S, Bishop H, Penn A, Naeije L, Kabbara N, Milne P, Hélias-Rodzewicz Z, Kolenova A, Renard C, Marec-Berard P, Thalhammer J, Pagnier A, Salmon A, Aladjidi N, Olivier L, Saultier P, Blanc L, Gandemer V, Schneider P, Hessissen L, Golan M, Elitzur S, Ben Arush M, Ashkenazi Lustig D, Dvir R, Raciborska A, Malas Z, Diallo S, Levy G, Efremova V, Munthe-Kaas MC, von Bahr Greenwood T, Felizzia GA, Braier JL, Boudiaf H, Ben Fraj I, Svojgr K, Krenova Z, Bernard F, Adam C, Karaoli E, Kristensen IA, Dahl C, Trambusti I, Gaspari S, De Fusco C, Chiaravalli S, Corti PC, Todesco A, Papadakis V, Luz I, Costa V, Osipova DS, Lyudovskikh E, Maschan MA, Bronin G, Burcev E, Idbaih A, Larabi IA, Bellouard M, Alvarez JC, Novosad O, Collin M, Henter JI, Emile JF, Heritier S, Minkov M
  • Revue Blood Adv
  • Date de publication 2026-02
Long-term MAPK inhibition of childhood refractory-Langerhans cell histiocytosis: an observational study on 288 patients.
  • Safety and efficacy of tamoxifen in patients with duchenne muscular dystrophy: open label extension of TAMDMD trial.

  • Auteurs Zwingli G, Putananickal N, Schmidt S, Nagy S, Rubino-Nacht D, Schaedelin S, Amthor H, Childs AM, Deconinck N, Horrocks I, Houwen-van Opstal S, Laugel V, Lopez Lobato M, Nascimento Osorio A, Schara-Schmidt U, Spinty S, von Moers A, Lawrence F, Hafner P, Dorchies OM, Fischer D, Henzi BC
  • Revue Neuromuscul Disord
  • Date de publication 2026-02
Safety and efficacy of tamoxifen in patients with duchenne muscular dystrophy: open label extension of TAMDMD trial.
  • Factors related to loss to follow-up and low compliance in Helicobacter pylori-infected children: The EuroPedHp Registry.

  • Auteurs Le Thi TG, Kotilea K, Cabral J, Kori M, Cilleruelo ML, Tavares M, Barrio J, Urbonas V, Homan M, Misak Z, Kalach N, Urruzuno P, Klemenak M, Krahl A, Chiaro A, Sykora J, Ugras MK, de Laffolie J, Miele E, Papadopoulou A, Koletzko S
  • Revue J Pediatr Gastroenterol Nutr
  • Date de publication 2026-02
Factors related to loss to follow-up and low compliance in Helicobacter pylori-infected children: The EuroPedHp Registry.
Bordet hospital

Institut Jules Bordet

Consultez toutes les publications scientifiques de Jules Bordet

Erasme hospital

Hôpital Erasme

Consulter toutes les publications scientifiques d'Erasme

Decorative image of doctor and patient

Toutes les publications scientifiques du H.U.B.

Consulter toutes les publications scientifiques du H.U.B.